Lysosome-targeting chimeras (LYTACs) hold therapeutic potential by degrading pathogenesis associated proteins, but current LYTAC systems often require case-by-case constructions and are devoid of a convenient and efficient modular platform. Here, the authors address these issues by developing a modular ferritin-based LYTAC platform for targeted degradation of membrane proteins for cancer therapy.
- Shuai Zhang
- Yiliang Jin
- Kelong Fan